# Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

> **NCT02802163** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02802163
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2020-09
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study drug unavailable
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802163, "Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02802163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*